ACTH Stimulation Test Results Reassessed
By LabMedica International staff writers Posted on 12 May 2018 |

Image: A diagram of types of adrenal insufficiency; CRH: corticotropin-releasing hormone, ACTH: adrenocorticotropic hormone (Photo courtesy of US National Institute of Health).
Cosyntropin (adrenocorticotropic hormone or ACTH) stimulation testing is considered the gold standard for investigating primary adrenal insufficiency (AI) and may be an effective alternative to insulin tolerance testing in the workup of secondary AI.
The time of day that ACTH stimulation testing takes place does not affect the percentages of failed, borderline, or passed results in the evaluation of AI. However, testing sites also have different practices about the time of day (morning versus afternoon) that ACTH testing takes place.
Scientists at Dalhousie University (Saint John, NB, Canada) conducted a retrospective study of all ACTH testing performed during a 10-year period to assess whether both 30- and 60-minute results are necessary and whether the timing of testing affects outcomes. In all, there were 431 ACTH stimulation tests; the team excluded 92 due to medications the patients were taking or because the patients had already been diagnosed with primary AI.
The cutoff for ACTH testing was 18 mcg/dL (500 nmol/L) with a test “fail” if both 30- and 60-minute results were below this level, a “borderline pass” if either a 30- or 60-minute value was below the cutoff, and a pass if results at both time frames were above the cutoff. The investigators considered the time of day in three blocks of time: early morning (between 08.00 and 10.00); late morning (between 10:01. and 12:00); and afternoon (after 12:00).
The scientists found that there were no differences at the different time intervals in mean cortisol levels at 30 (574.5, 559, 534 nmol/L, respectively) and 60 minutes (642, 623, 619 nmol/L, respectively) between groups. When comparing 30- versus. 60-min values using a cut-off of ≥500 nmol/L, 45 patients (13.4%) failed to reach the cut-off at 30 minutes, but met the cut-off at 60 minutes. Conversely, only two patients (0.6%) who met the cut-off at 30 minutes failed to reach it at 60 minutes.
The authors concluded that outcomes from ACTH testing are not affected by time of day. Furthermore, using a 30-minutes cortisol level in isolation results in more than one in seven patients having a false positive diagnosis of AI; a 60-minutes value of ≥500 nmol/L alone may be sufficient to diagnose AI in more than 99% of cases. The study was published in the April 2018 issue of the journal Clinical Biochemistry.
Related Links:
Dalhousie University
The time of day that ACTH stimulation testing takes place does not affect the percentages of failed, borderline, or passed results in the evaluation of AI. However, testing sites also have different practices about the time of day (morning versus afternoon) that ACTH testing takes place.
Scientists at Dalhousie University (Saint John, NB, Canada) conducted a retrospective study of all ACTH testing performed during a 10-year period to assess whether both 30- and 60-minute results are necessary and whether the timing of testing affects outcomes. In all, there were 431 ACTH stimulation tests; the team excluded 92 due to medications the patients were taking or because the patients had already been diagnosed with primary AI.
The cutoff for ACTH testing was 18 mcg/dL (500 nmol/L) with a test “fail” if both 30- and 60-minute results were below this level, a “borderline pass” if either a 30- or 60-minute value was below the cutoff, and a pass if results at both time frames were above the cutoff. The investigators considered the time of day in three blocks of time: early morning (between 08.00 and 10.00); late morning (between 10:01. and 12:00); and afternoon (after 12:00).
The scientists found that there were no differences at the different time intervals in mean cortisol levels at 30 (574.5, 559, 534 nmol/L, respectively) and 60 minutes (642, 623, 619 nmol/L, respectively) between groups. When comparing 30- versus. 60-min values using a cut-off of ≥500 nmol/L, 45 patients (13.4%) failed to reach the cut-off at 30 minutes, but met the cut-off at 60 minutes. Conversely, only two patients (0.6%) who met the cut-off at 30 minutes failed to reach it at 60 minutes.
The authors concluded that outcomes from ACTH testing are not affected by time of day. Furthermore, using a 30-minutes cortisol level in isolation results in more than one in seven patients having a false positive diagnosis of AI; a 60-minutes value of ≥500 nmol/L alone may be sufficient to diagnose AI in more than 99% of cases. The study was published in the April 2018 issue of the journal Clinical Biochemistry.
Related Links:
Dalhousie University
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more